Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy.
Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy.
复制标题
红细胞铁蛋白和网织红细胞测量在监测静脉铁剂治疗反应中的评估。
DOI：
10.1016/s0272-6386(97)90087-1
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
J. Turney
中科院分区：
文献类型：
--
作者：
S. Bhandari;Norfolk Derek;A. Brownjohn;J. Turney
静脉(IV)铁剂治疗可以减少透析患者对促红细胞生成素(EPO)的需求。准确监测这种反应是困难的。红细胞铁蛋白(RBCFer)和网织红细胞指数的估计可能会为红细胞(红血球)铁的可获得性提供更有价值的信息。在一项前瞻性的非盲法研究中，我们评估了RBCFer、网织红细胞平均血红蛋白含量(CHR)和网织红细胞平均血红蛋白浓度(CHCMR)的使用，对22名血液透析患者(男性16名，女性6名，平均年龄62岁，范围24-80岁)进行了研究。所有患者的初始血清铁蛋白为≤60μg/L，排除了具有促红细胞生成素抵抗和潜在出血/血液学疾病特征的患者。患者接受皮下促红细胞生成素治疗，并接受静脉铁剂治疗。平均血红蛋白水平在整个研究过程中保持不变(P=0.087)。血清铁蛋白和RBCFer显著升高(P<；分别为0.001和0.015)，而转铁蛋白饱和度在研究结束时显著降低(P=0.0047)。网织红细胞在开始静脉补铁后的前14天急剧增加，而低慢性红细胞的百分比开始下降。RBCFer的早期下降是显而易见的。随着静脉注射铁的增加，Chr增加，这表明对发育中的红细胞的铁供应增加。RbCFer和Chr的测定提供了静脉铁剂治疗期间红细胞生成铁供应增加的证据。这些措施有助于识别功能性铁缺乏症患者，并允许更准确地监测静脉注射铁治疗的反应。
Intravenous (IV) iron therapy can reduce erythropoietin (EPO) requirements in dialysis patients. Monitoring this response accurately is difficult. Estimation of red blood cell ferritin (RBCFer) and reticulocyte indices may give additional valuable information about iron availability to the erythroblasts (erythron). We evaluated the use of RBCFer, mean hemoglobin content of reticulocytes (CHr), and mean hemoglobin concentration of reticulocytes (CHCMr) in a prospective, nonblinded study of 22 hemodialysis patients (16 men and six women with a mean age of 62 years [range, 24 to 80 years]). All patients had an initial serum ferritin of ≤ 60 μg/L. Patients with features known to produce EPO resistance and underlying bleeding/hematologic disorders were excluded. Patients were established on subcutaneous EPO and given IV iron therapy. The mean hemoglobin level remained constant throughout the study (P = 0.087). Serum ferritin and RBCFer increased significantly (P < 0.001 and 0.015, respectively) while a reduction in transferrin saturation became significant at the end of the study (P = 0.0047). A sharp increase in reticulocytes occurred in the first 14 days after commencement of IV iron, and there was an initial decrease in the percentage of hypochronic RBCs. An early decline in RBCFer was apparent. CHr increased with IV iron, indicative of increased iron supply to the developing erythron. Measurement of RBCFer and CHr provide evidence of increased iron supply for erythropoiesis during IV iron therapy. These measures help identify patients with functional iron deficiency and allow more accurate monitoring of response to IV iron therapy.
DOI：
--
发表时间：
--
期刊：
影响因子：
--
作者：
通讯作者：
--